PlumX Metrics
Embed PlumX Metrics

Role of the P2Y receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes

Stem Cells, ISSN: 1066-5099, Vol: 31, Issue: 12, Page: 2747-2758
2013
  • 57
    Citations
  • 0
    Usage
  • 55
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Accumulating evidence indicates that extracellular nucleotides, signaling through purinergic receptors, play a significant role in bone remodeling. Mesenchymal stem cells (MSCs) express functional P2Y receptors whose expression level is regulated during osteoblast or adipocyte differentiation. P2Y13-deficient mice were previously shown to exhibit a decreased bone turnover associated with a reduction in the number of both osteoblasts and osteoclasts on the bone surfaces. We therefore examined whether P2Y13R activation was involved in the osteogenic differentiation of MSC. Our study demonstrated that ADP stimulation of P2Y13R (but not P2Y13R) adherent bone marrow stromal cells (BMSCs) increased significantly the formation of alkaline phosphatase-colony-forming units (CFU-ALP) as well as the expression of osteoblastic markers (osterix, alkaline phosphatase, and collagen I) involved in the maturation of preosteoblasts into osteoblasts. The number of CFU-ALP obtained from P2Y13R BMSC and the level of osteoblastic gene expression after osteogenic stimulation were strongly reduced compared to those obtained in wild-type cell cultures. In contrast, when P2Y13R BMSCs were incubated in an adipogenic medium, the number of adipocytes generated and the level of adipogenic gene expression (PPARc2 and Adipsin) were higher than those obtained in P2YR MSC. Interestingly, we observed a significant increase of the number of bone marrow adipocytes in tibia of P2YR mice. In conclusion, our findings indicate that the P2YR plays an important role in the balance of osteoblast and adipocyte terminal differentiation of bone marrow progenitors. Therefore, the P2Y receptor can be considered as a new pharmacological target for the treatment of bone diseases like osteoporosis. © AlphaMed Press.

Bibliographic Details

Biver, Galadrielle; Wang, Ning; Gartland, Alison; Orriss, Isabel; Arnett, Timothy R; Boeynaems, Jean-Marie; Robaye, Bernard

Oxford University Press (OUP)

Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know